{"product_id":"non-alcoholic-fatty-liver-disease-isbn-9780470673171","title":"Non-Alcoholic Fatty Liver Disease","description":"\u003cp\u003eThe sharp rise in cases of Non-alcoholic fatty liver disease is fast becoming one of the major concerns for hepatologists worldwide. This comprehensive clinical guide explains how to diagnose NAFLD and manage patients according to the best standards of care. Contributors from the world's leading institutions concentrate on patient care, drawing on their extensive experience.\u003c\/p\u003e  \u003cp\u003eList of Contributors, vii\u003c\/p\u003e \u003cp\u003e1 What is non-alcoholic fatty liver disease (NAFLD), and why is it important? 1\u003cbr\u003e \u003ci\u003eGeoffrey C. Farrell, Arthur J. McCullough, and Christopher P. Day\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 NAFLD in the community, 17\u003cbr\u003e \u003ci\u003eLeon A. Adams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Pathology of NAFLD, 27\u003cbr\u003e \u003ci\u003eElizabeth M. Brunt and David E. Kleiner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 The natural history of NAFLD, 37\u003cbr\u003e \u003ci\u003ePaul Angulo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH), 46\u003cbr\u003e \u003ci\u003eIsabelle A. Leclercq\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Diabetes and NAFLD: why is the connection important? 62\u003cbr\u003e \u003ci\u003eElisabetta Bugianesi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 NAFLD and cardiovascular risk factors: implications for vascular disease, 71\u003cbr\u003e \u003ci\u003eGiovanni Targher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer, 84\u003cbr\u003e \u003ci\u003eShivakumar Chitturi and Geoffrey C. Farrell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Imaging of NAFLD, 93\u003cbr\u003e \u003ci\u003eTakeshi Yokoo, An Tang, and Claude B. Sirlin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Non-invasive methods to determine the severity of NAFLD and NASH, 112\u003cbr\u003e \u003ci\u003eVincent Wai-Sun Wong and Henry Lik-Yuen Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Fatigue, quality of life, and psychosocial issues for people with NAFLD, 122\u003cbr\u003e \u003ci\u003eJulia L. Newton and James Frith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Physical activity and cardiovascular fi tness in patients with NAFLD: clinical importance and therapeutic implications, 132\u003cbr\u003e \u003ci\u003eIngrid J. Hickman, Graeme A. Macdonald, and Nuala M. Byrne\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 NAFLD, obesity, and bariatric surgery, 149\u003cbr\u003e \u003ci\u003ePhilippe Mathurin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management, 157\u003cbr\u003e \u003ci\u003eQuentin M. Anstee, Ann K. Daly, and Christopher P. Day\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 NAFLD in children, 171\u003cbr\u003e \u003ci\u003eAriel E. Feldstein\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure, 182\u003cbr\u003e \u003ci\u003eJonathon W. Schwake, Dawn M. Torres, and Stephen A. Harrison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers, 192\u003cbr\u003e \u003ci\u003eJanine Graham and Helen L. Reeves\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 NAFLD in Chinese and South Asian people, 206\u003cbr\u003e \u003ci\u003eJia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Non-alcoholic fatty liver disease in Japan, 217\u003cbr\u003e \u003ci\u003eTakeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Non-alcoholic fatty liver disease in South America and Hispanic people, 228\u003cbr\u003e \u003ci\u003eHelma Pinchemel Cotrim and Carla Daltro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care?, 234\u003cbr\u003e \u003ci\u003eAchuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J. McCullough\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Dietary factors in the pathogenesis and care of patients with fatty liver disease, 248\u003cbr\u003e \u003ci\u003eGiulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, and Silvia Di Domizio\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Metabolic factors and steatosis in patients with hepatitis B and C, 260\u003cbr\u003e \u003ci\u003eFrancesco Negro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones), 271\u003cbr\u003e \u003ci\u003eMohammad S. Siddiqui and Arun J. Sanyal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines, 284\u003cbr\u003e \u003ci\u003eAnne Catherine Bürgi and Jean-François Dufour\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents, 293\u003cbr\u003e \u003ci\u003eGiovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, and Maurizio Cassader\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 308\u003c\/p\u003e \u003cp\u003eColor plate section facing p86\u003c\/p\u003e  \u003cp\u003e“This book is useful for anyone who cares for patients with NAFLD -- specialist or generalist. It provides both a general overview as well as a detailed look at disease mechanisms, clinical assessment, diagnosis, and treatment. It comes out in a timely fashion as diseases such as diabetes, obesity, metabolic syndrome, NAFLD, and NASH are on the rise.”  (\u003ci\u003eDoody’s\u003c\/i\u003e, 24 January 2014)\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeoff Farrell, Professor of Hepatic Medicine, Director of Gastroenterology, The Canberra Hospital, Australia\u003c\/b\u003e\u003cbr\u003eGeoffrey Farrell graduated MB BS from the University of Tasmania in 1970, and trained in gastroenterology and hepatology at the Royal Prince Alfred and Royal Brisbane Hospitals, the latter with Lawrie Powell with whom he completed an MD on hepatic drug metabolism. He was awarded an NHMRC CJ Martin Fellowship to conduct post-doctoral research in UCSF, and in 1980 returned to Sydney to establish a Liver Research Group at Westmead Hospital. He was promoted to a personal chair in 1993, then accepted the Storr Chair in Hepatic Medicine. He remained Director of the Storr Liver Unit until Jan 2006, when he accepted the position as Professor of Hepatic Medicine with ANU Medical School and Director of Gastroenterology and Hepatology at The Canberra Hospital. He has held many leadership roles in medical research, gastroenterology, editorial boards, and academic medicine, including Editor-in-Chief of \u003ci\u003eJournal of Gastroenterology and Hepatology\u003c\/i\u003e since November 2006.\u003cbr\u003eGeoff Farrell's research interests are in non-alcoholic steatohepatitis, viral hepatitis, drug-induced liver injury, and liver regeneration. He has published 3 books, including the first on non-alcoholic fatty liver disease, and written more than 180 scientific papers and 100 reviews\/chapters and editorials in the fields of hepatology and biochemical pharmacology. His work is very highly cited, with an H-index of 50, more than 20 articles cited \u0026gt;100 times, average citation 32 per paper, and 15 articles being the subject of editorials in major medical journals. He is CIA on an NHMRC Program Grant to study the molecular and cellular basis of liver disease, and has recently held a Centre for Clinical Research Excellence Program grant to improve outcomes for patients with liver disease.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eArthur McCullough, Department Chair of Gastroenterology and Hepatology, Cleveland Clinic, USA\u003c\/b\u003e\u003cbr\u003eArthur McCullough, MD, is Department Chair of Gastroenterology and Hepatology and a Staff Physician in the Department of Pathobiology and Transplantation Center at Cleveland Clinic. He was appointed in 2006. He attended medical school at SUNY Health Science Center at University Hospital of Syracuse, N.Y. He completed his internship and residency at Cleveland Clinic and a fellowship at Mayo Clinic in Rochester, Minn.\u003cbr\u003eHe is one of the most senior hepatologists in the United States and is the current President of the American Association for the Study of Liver Diseases. Other significant achievements are: Best Doctor's in America: \"Midwest Region\" annually from 1996-2008; Chair of the NIH-funded Clinical Research Network on Fatty Liver Disease (federal funding); NIH Grant on Omega 3 Fatty Acids in Diabetes (federal funding); New Novel Agents for Hepatitis C Patients who failed to respond to previous therapy (non-federal funding)\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChristopher Day, Pro-Vice-Chancellor for the Faculty of Medical Sciences, Professor of Liver Medicine and Consultant Hepatologist, School of Clinical Medical Sciences, Newcastle University, UK\u003c\/b\u003e\u003cbr\u003eChris Day qualified from Cambridge University in 1983 and subsequently trained in General Medicine and Hepatology at Newcastle, becoming Consultant Hepatologist in the Liver Unit at Newcastle’s Freeman Hospital in 1994 and Professor of Liver Medicine at University of Newcastle University in 2000. He was formerly Head of the School of Clinical Medical Sciences at the University and since April 2008 has been Pro-Vice-Chancellor of the Faculty of Medical Sciences. Professor Day's research interests focus largely on fatty liver disease related both to obesity and to alcohol, with additional interests in drug-induced liver injury and liver fibrosis. His work has been funded by the MRC and the Wellcome Trust and he is a former MRC Clinical Training Fellow and Clinician Scientist Fellow. In 1999 he was the Goulstonian Lecturer of the Royal College of Physicians and in 2000 was awarded the research gold medal of the British Society of Gastroenterology. He is a Fellow and Councillor of the Academy of Medical Sciences, an Executive Member of the Medical Schools Council and an NIHR Senior Investigator. He is also Chief Editor of the \u003ci\u003eJournal of Hepatology\u003c\/i\u003e, and is on both the Populations and Systems Medicine Board and the Translational Stem Cell Research Committee of the Medical Research Council.\u003c\/p\u003e  \u003cp\u003e\u003ci\u003eDo you have patients referred to you suffering from NAFLD?\u003cbr\u003e \u003c\/i\u003e\u003ci\u003eAre you looking for an expert guide to the latest in clinical management?\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIf so, this is the book for you, providing an expert and comprehensive analysis of NAFLD: what it is, why it happens, who is likely to suffer from it, and how to decide on the best management options for your patients.\u003c\/p\u003e \u003cp\u003eThis book focuses clearly on providing first-rate clinical guidance as to the assessment, diagnosis and treatment of patients in the clinical setting, based wherever possible on the latest evidence and scientific understanding of disease mechanisms.  With each chapter fully revised and updated with the very latest in AASLD,  EASL and Asia-Pacific guidelines, this second edition provides:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eFour brand new chapters, including “NAFLD and cardiovascular risk factors” and “Non-invasive methods to determine severity of NAFLD\/ NASH”\u003c\/li\u003e \u003cli\u003eA clear overview on the causative mechanisms of NAFLD\u003c\/li\u003e \u003cli\u003eSelf-assessment via key points and multiple-choice questions throughout\u003c\/li\u003e \u003cli\u003eThe very latest in clinical drug trials\u003c\/li\u003e \u003cli\u003eAnalysis of NAFLD in relation to obesity, diabetes, high cholesterol and liver cancer\u003c\/li\u003e \u003cli\u003eA consideration of NAFLD importance in Asia (particularly including Japan and China) and South America, as well as Europe and North America\u003c\/li\u003e \u003c\/ul\u003e NAFLD is a serious condition that is increasing in prevalence globally from year to year\u003ci\u003e.  Non-Alcoholic Fatty Liver Disease:\u003c\/i\u003e \u003ci\u003eA Practical Guide,\u003c\/i\u003e is essential reading for all hepatologists and health professionals managing patients who have this condition.","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989694038245,"sku":"NP9780470673171","price":184.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470673171.jpg?v=1761785132","url":"https:\/\/k12savings.com\/es\/products\/non-alcoholic-fatty-liver-disease-isbn-9780470673171","provider":"K12savings","version":"1.0","type":"link"}